By Anna Greene, PhD, NETRF Director of Research The landscape of biomedical research is undergoing a seismic shift. This year alone, the NIH has awarded

At NETRF, our annual Request for Applications (RFA) is a cornerstone of our mission to fund innovative research in neuroendocrine cancer. This two-stage process is

By Anna Greene, PhD, Director of Research, NETRF Pancreatic neuroendocrine tumors (PanNETs) are a rare but increasingly detected cancer, thanks in part to more widespread

By Anna Greene, PhD, NETRF Director of Research Unlocking the Molecular Mysteries of Neuroendocrine Neoplasms (NENs)  A study published this month by NETRF-funded Collaborative Grant

Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade disease.

Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re

In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the

Lung neuroendocrine tumors (lung NETs) make up 20-30% of all neuroendocrine cancers, yet their diversity and complexity have long puzzled researchers and clinicians. Now, thanks

A new clinical trial at the University of Chicago Medicine is evaluating the combination of 177Lu-DOTATATE with fulvestrant in patients with advanced pancreatic neuroendocrine tumors